Silencing HIF-1α Makes Erlotinib Work Better Against Lung Cancer Cells

Lung cancer researchers have reported a laboratory strategy that pairs a gene-silencing molecule with a widely used targeted drug, and the combination outperformed either treatment alone in non-small cell lung cancer cells. The new study, published in the journal Drugs in R&D, focused on hypoxia-inducible factor-1α, or HIF-1α, a protein that helps tumor cells survive in the oxygen-starved interiors of solid tumors and that has long been implicated in resistance to EGFR-targeted therapies. The work is entirely preclinical: it was conducted in cell lines and with public database analyses, not in patients, so the findings are a proof of concept rather than a demonstrated clinical benefit.

The team, led by Haojie Jiang, Shunhui Cai and colleagues with senior author Yiqiao Hu, began by establishing that HIF-1α is abundant in non-small cell lung cancer, which accounts for roughly 85 percent of lung cancer cases. Mining transcriptome data from the TCGA database for 982 patients with non-small cell lung cancer, including 501 lung squamous cell carcinoma and 481 lung adenocarcinoma cases, the researchers found that HIF-1α messenger RNA levels were significantly higher in tumor tissues than in adjacent normal tissue, a pattern that held in both histological subtypes. In a separate set of 184 clinical samples with complete follow-up, patients whose tumors expressed high levels of HIF-1α had significantly shorter median overall survival than patients with low expression, based on Kaplan–Meier analysis.

Experimental measurements echoed the database findings. Compared with MRC-5 human embryonic lung fibroblasts, the H1975 lung cancer cell line showed HIF-1α messenger RNA levels 15.2 times higher and the A549 line 8.0 times higher, with corresponding increases at the protein level by western blot. Notably, H1975 cells carry both the L858R and T790M mutations in EGFR, a combination that confers resistance to erlotinib and related tyrosine kinase inhibitors, making them a standard laboratory model of drug-resistant disease. Under hypoxic conditions of 5 percent oxygen, HIF-1α protein levels rose further over time.

Bioinformatic comparisons of HIF-1α high- and low-expression groups in a TCGA cohort of 1005 non-small cell lung cancer patients showed that six downstream genes were significantly upregulated when HIF-1α was high: SLC2A1, which encodes the glucose transporter GLUT1; PDK1, which inhibits mitochondrial oxidative phosphorylation; VEGFA, a driver of angiogenesis; CA9, which regulates extracellular pH; and MMP2 and MMP9, enzymes that degrade the extracellular matrix and facilitate invasion. Pathway enrichment analyses linked high HIF-1α expression to metabolic reprogramming, immune microenvironment remodeling and intercellular communication, painting the protein as a central regulatory hub rather than a single-purpose switch.

One sequence, siRNA-HIF1α-2367, produced the strongest knockdown of both HIF-1α protein and messenger RNA in H1975 cells 48 hours after transfection and was selected for all subsequent experiments. The functional consequences were substantial: proliferation of H1975 cells was inhibited by 43.4 percent at 48 hours, the apoptotic fraction rose to 11.02 percent, and the invasive area in Transwell assays fell to 8 percent of control levels.

The metabolic signature of the cancer cells shifted as well. Reverse transcription-quantitative PCR and western blotting confirmed that GLUT1, PDK1, VEGFA, CA9, MMP2 and MMP9 were all significantly downregulated after HIF-1α silencing. Lactate released into the culture medium, a readout of glycolytic flux, dropped by 19.1 percent at 24 hours and 27.6 percent at 48 hours, indicating a time-dependent suppression of the Warburg effect, the aerobic glycolysis that tumor cells favor even when oxygen is available. HIF-1α knockdown also significantly reduced intracellular reactive oxygen species under hypoxic conditions, which the authors interpret as an alleviation of oxidative stress and a restoration of redox balance.

A second line of experiments addressed how EGFR signaling controls HIF-1α in the first place. Because H1975 cells carry the erlotinib-resistant L858R/T790M double mutation, the researchers used the EGFR wild-type A549 line to study the regulatory relationship. Treating A549 cells with erlotinib inhibited phosphorylation of EGFR and its downstream PI3K/AKT and MEK/ERK pathways, and this was accompanied by a decrease in HIF-1α protein. Pharmacologic confirmation followed with the PI3K inhibitor LY294002 and the MEK inhibitor U0126, which together showed that the two signaling axes additively support the stability of HIF-1α protein. In other words, EGFR signaling does not merely coexist with HIF-1α; it actively helps keep the resistance-associated protein in place.

That mechanistic link set up the central combination experiment. In H1975 cells, erlotinib alone or HIF-1α siRNA alone each partially inhibited proliferation and invasion and induced some apoptosis. The combination, however, was markedly stronger: cell viability fell to 41.9 percent, the apoptosis rate climbed to 12.65 percent, and the invasion area shrank further to 6.61 percent. The combined treatment also more potently suppressed HIF-1α itself and its downstream metabolic targets GLUT1, PDK1, CA9 and MMP2, suggesting that the two agents attack the resistance machinery from complementary directions, one blocking the upstream driver signaling and the other removing the hypoxia-driven survival program.

The authors frame the result as a strategy to reverse hypoxia-induced drug resistance by disrupting metabolic reprogramming and hypoxia adaptation simultaneously with EGFR inhibition. They are careful to note the limitations of the work. All efficacy data come from in vitro experiments in two cell lines, and in vivo validation is needed to assess whether the approach works and is safe in a living organism. The upstream regulatory network around HIF-1α, involving PI3K, mTOR and MAPK, is highly interconnected and may contain feedback loops that a two-cell-line study cannot capture, and the authors call for deeper dissection of these pathways and for work on optimized combinations and patient stratification.

Even with those caveats, the study adds a concrete data point to a growing body of evidence that HIF-1α is more than a bystander in EGFR tyrosine kinase inhibitor resistance. The survival association in 184 clinical samples, the consistent overexpression across database and cell-line analyses, and the synergistic effect of siRNA plus erlotinib in resistant H1975 cells together argue that hypoxia signaling is a legitimate vulnerability worth targeting alongside driver mutations. Whether HIF-1α silencing can be delivered safely and effectively to human tumors remains the decisive unanswered question, but the combination logic, hitting both the oncogenic signal and the metabolic adaptation it feeds, offers a clear template for the next round of preclinical testing.

Subject of Research: HIF-1α siRNA combined with erlotinib to overcome hypoxia-driven drug resistance in non-small cell lung cancer cells

Article Title: HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance

Article References: Jiang, H., Cai, S., Zhang, X., Chen, S., Yue, C., Yin, W., & Hu, Y. (2026). HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance. Drugs in R&D, 26(1), 101-115. https://doi.org/10.1007/s40268-025-00534-5

Image Credits: AI Generated

DOI: 10.1007/s40268-025-00534-5

Keywords: HIF-1α, siRNA, erlotinib, non-small cell lung cancer, EGFR tyrosine kinase inhibitor, drug resistance, hypoxia, Warburg effect, glycolysis, PI3K/AKT, MEK/ERK, preclinical study